Colorectal NeoplasmsNCT07239479
DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy
A study testing Dexmedetomidine + Desflurane and Desflurane + Normal Saline in people with Colorectal Neoplasms, run by Tam Anh Research Institute at 1 site in Vietnam.
Trial summary
This randomized double-blind controlled clinical trial aims to evaluate the efficacy and safety of combining Dexmedetomidine with Desflurane in patients undergoing elective laparoscopic colectomy. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Colorectal Neoplasms
- What is being tested?
- Dexmedetomidine + Desflurane and Desflurane + Normal Saline
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteVietnam
- Study dates
- 1 Dec 2025to 30 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18-65 years
- ASA Physical Status I-II
- Elective laparoscopic colectomy
- Written informed consent provided
Who cannot join
- Severe cardiac, hepatic, or renal disease
- COPD or bronchial asthma
- Chronic opioid or psychotropic medication use
- Atrioventricular block (grade II-III), sick sinus syndrome
- Significant intraoperative bleeding or hemodynamic instability
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Vietnam1 site, 1 recruiting
- Recruiting
Tam Anh TP. Ho Chi Minh General Hospital
Ho Chi Minh City, Ho Chi Minh, 700000
Phan Quoc Thai, MD, thaipq@tahospital.vn
About this study
Official title: Efficacy and Safety of Dexmedetomidine Combined With Desflurane in Laparoscopic Colectomy: A Randomized Double-Blind Controlled Clinical Trial (DEXDES Trial)
This randomized double-blind controlled clinical trial aims to evaluate the efficacy and safety of combining Dexmedetomidine with Desflurane in patients undergoing elective laparoscopic colectomy. The study will assess whether the combination can reduce Desflurane consumption, improve intraoperative hemodynamic stability, and enhance postoperative recovery compared to Desflurane alone.
Read the detailed description
Dexmedetomidine, a selective alpha-2 adrenergic agonist, has sedative and analgesic properties without significant respiratory depression. Desflurane, a volatile anesthetic with low blood-gas solubility, allows rapid induction and emergence. Combining these two agents may provide anesthetic-sparing effects and promote faster postoperative recovery under ERAS protocols. This study will enroll 40 adult patients undergoing elective laparoscopic colectomy at Tam Anh General Hospital, Vietnam. Participants will be randomized into two groups: Dexmedetomidine + Desflurane versus Desflurane alone. The primary outcome is average Desflurane consumption per hour, with secondary outcomes including hemodynamic parameters, Fentanyl use, emergence quality, and incidence of postoperative nausea and vomiting.
- Conditions
- Colorectal Neoplasms
- Being tested
- Dexmedetomidine + Desflurane, Desflurane + Normal Saline
- Keywords
- Dexmedetomidine, Desflurane, General anesthesia, Colorectal surgery, ERAS, Hemodynamic stability
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dexmedetomidine + DesfluraneDrug
Dexmedetomidine bolus 1 µg/kg IV over 15 minutes before induction, followed by continuous infusion 0.5 µg/kg/h during surgery.
Desflurane administered at 1 MAC with EtControl mode.
Desflurane + Normal SalineDrug
Normal saline infusion with identical timing and volume as the intervention group.
Desflurane administered at 1 MAC with EtControl mode.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Experimental | Arm 1 - Dexmedetomidine + Desflurane (Intervention Group):
Dexmedetomidine bolus 1 µg/kg IV over 15 minutes before induction, followed by continuous infusion 0.5 µg/kg/h during surgery.
Desflurane administered at 1 MAC with EtControl mode. Receives: Drug: Dexmedetomidine + Desflurane |
| Control Group | Placebo comparator | Arm 2 - Desflurane + Normal Saline (Control Group):
Normal saline infusion with identical timing and volume as the intervention group.
Desflurane administered at 1 MAC with EtControl mode Receives: Drug: Desflurane + Normal Saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average Desflurane consumption per hour (mL/h) during surgery.
Average Desflurane consumption per hour (mL/h) during surgery.
Measured: During surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2025
- Study start1 Dec 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion30 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tam Anh Research Institute
- Sponsor type
- University, hospital or other
- Collaborators
- Tam Anh TP. Ho Chi Minh General Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07239479
- Sponsor's protocol ID
- TA2.25.11
- Status last verified
- Nov 2025
- First submitted
- 16 Nov 2025
- Last updated
- 30 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual patient data (IPD) will remain confidential. Aggregated, de-identified data may be shared upon reasonable request after study completion for academic purposes.
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Dexmedetomidine Combined With Desflurane in Laparoscopic Colectomy: A Randomized Double-Blind Controlled Clinical Trial (DEXDES Trial)
- ClinicalTrials.gov ID
- NCT07239479
- Acronym / sponsor ID
- TA2.25.11
- Conditions
- Colorectal Neoplasms
- Keywords
- Dexmedetomidine, Desflurane, General anesthesia, Colorectal surgery, ERAS, Hemodynamic stability
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Tam Anh Research InstituteUniversity, hospital or other
- Collaborators
- Tam Anh TP. Ho Chi Minh General Hospital
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 30 Jan 2027 (estimated)
- First posted
- 20 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized double-blind controlled clinical trial aims to evaluate the efficacy and safety of combining Dexmedetomidine with Desflurane in patients undergoing elective laparoscopic colectomy. The study will assess whether the combination can reduce Desflurane consumption, improve intraoperative hemodynamic stability, and enhance postoperative recovery compared to Desflurane alone.
Detailed description
Dexmedetomidine, a selective alpha-2 adrenergic agonist, has sedative and analgesic properties without significant respiratory depression. Desflurane, a volatile anesthetic with low blood-gas solubility, allows rapid induction and emergence. Combining these two agents may provide anesthetic-sparing effects and promote faster postoperative recovery under ERAS protocols. This study will enroll 40 adult patients undergoing elective laparoscopic colectomy at Tam Anh General Hospital, Vietnam. Participants will be randomized into two groups: Dexmedetomidine + Desflurane versus Desflurane alone. The primary outcome is average Desflurane consumption per hour, with secondary outcomes including hemodynamic parameters, Fentanyl use, emergence quality, and incidence of postoperative nausea and vomiting.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Experimental | Drug: Dexmedetomidine + DesfluraneArm 1 - Dexmedetomidine + Desflurane (Intervention Group): Dexmedetomidine bolus 1 µg/kg IV over 15 minutes before induction, followed by continuous infusion 0.5 µg/kg/h during surgery. Desflurane administered at 1 MAC with EtControl mode. |
| Control Group | Placebo comparator | Drug: Desflurane + Normal SalineArm 2 - Desflurane + Normal Saline (Control Group): Normal saline infusion with identical timing and volume as the intervention group. Desflurane administered at 1 MAC with EtControl mode |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age 18-65 years
- ASA Physical Status I-II
- Elective laparoscopic colectomy
- Written informed consent provided
Key exclusion criteria (5 listed)
- Severe cardiac, hepatic, or renal disease
- COPD or bronchial asthma
- Chronic opioid or psychotropic medication use
- Atrioventricular block (grade II-III), sick sinus syndrome
- Significant intraoperative bleeding or hemodynamic instability
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dexmedetomidine + DesfluraneDexmedetomidine bolus 1 µg/kg IV over 15 minutes before induction, followed by continuous infusion 0.5 µg/kg/h during surgery. Desflurane administered at 1 MAC with EtControl mode. | Drug | Intervention Group |
| Desflurane + Normal SalineNormal saline infusion with identical timing and volume as the intervention group. Desflurane administered at 1 MAC with EtControl mode. | Drug | Control Group |
Primary outcome
Average Desflurane consumption per hour (mL/h) during surgery.
Time frame: During surgery
Average Desflurane consumption per hour (mL/h) during surgery.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2025.
- Individual participant dataSharing planned: No. Individual patient data (IPD) will remain confidential. Aggregated, de-identified data may be shared upon reasonable request after study completion for academic purposes.
Related trials for Colorectal Neoplasms
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dexmedetomidine + Desflurane and Desflurane + Normal Saline in people with Colorectal Neoplasms, run by Tam Anh Research Institute at 1 site in Vietnam.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Phan Quoc Thai, MD (+84 964 152 360, thaipq@tahospital.vn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average Desflurane consumption per hour (mL/h) during surgery. (time frame: During surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2025.